Clinical Study of Core Blood-derived IL-10 CD19-CAR NK in the Treatment of Refractory/Relapsed Autoimmune Diseases
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study is a single-center, open-label, single-arm, dose-escalation trial. The aim of this study is to investigate the safety and efficacy of anti-CD19 IL-10 CAR-NK cells in patients with refractory/relapsed autoimmune diseases, including systemic sclerosis, idiopathic inflammatory myositis, ANCA associated vasculitis, sjogren syndrome, and antiphospholipid syndrome.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Tumor-associated myositis (myositis occurring within 2 years of diagnosis of tumor).
Locations
Other Locations
China
the second affiliated hospital Zhejiang University School of Medicine
RECRUITING
Hangzhou
Contact Information
Primary
Jing Xue, MD.,
jingxue@zju.edu.cn
+86-13758121751
Time Frame
Start Date: 2025-01-06
Estimated Completion Date: 2027-01-06
Participants
Target number of participants: 15
Treatments
Experimental: Participant Group
anti-CD19 CAR-NK cells
Related Therapeutic Areas
Sponsors
Leads: Second Affiliated Hospital, School of Medicine, Zhejiang University